Subscribe
VBCR - Conference Highlights - ACR 2013, Lupus

Patients with systemic lupus erythematosus (SLE) frequently require corticosteroids as standard therapy. One question that remains is whether treatment with belimumab facilitates a tapering of or the discontinuation of corticosteroid therapy. This has been a controversial issue in 2 presentations at the 2013 annual meeting of the American College of Rheumatology held in San Diego, California from October 25-30, showing evidence that belimumab does (Abstract 1740) and does not (Abstract 1605) enable discontinuation of corticosteroid therapy in patients with SLE.

In another report presented by van Vollenhoven and colleagues (Abstract 1585), pooled data were analyzed from the BLISS-52 and BLISS-76 trials, which assessed the effects of treatment with belimumab on corticosteroid dosing across 52 weeks.

In the 2 BLISS studies, patients treated with corticosteroids at baseline were randomized to receive belimumab 10 mg/kg plus standard therapy (N = 478) or placebo plus standard therapy (N = 488). The patients in the 2 BLISS trials had active SLE (ie, SLELNA-SLEDAI scores of >6), and were 94% female, with a mean age of 37.1 years and a mean daily corticosteroid dose of 12.5 mg.

Based on the pooled data from these studies, the mean of all cumulative decreases in corticosteroid dose was 741 mg in the belimumab group versus 542 mg in the placebo group (P = .017). The mean of all cumulative increases in corticosteroid dose was 1272 mg in the belimumab group versus 1458 mg in the placebo group (P <.001). The mean cumulative change from baseline in corticosteroid dose was 531 mg in the belimumab group versus 916 mg in the placebo group (P <.001). The mean change from baseline in average daily corticosteroid dose was 1.46 mg in the belimumab group and 2.51 mg in the placebo group (P <.001).

Therefore, although there was an increase in total corticosteroid dose in the belimumab and in the placebo groups over the 52-week duration of the BLISS trials, the increase was significantly smaller in patients who received belimumab plus standard therapy than in patients receiving standard therapy alone.

These results underscore the fact that for patients with moderately active SLE, long-term corticosteroid use is not only a reality but also a major determinant of long-term clinical outcome. However, patients with SLE who are receiving belimumab are able to significantly lower their requirements for increased corticosteroid dose compared with patients who receive placebo, which may have a significant clinical relevance. It will be interesting to follow the postmarketing experience with belimumab to see if these positive effects on corticosteroid dose requirements are replicated in routine clinical practice in academic lupus centers or in community rheumatology offices.

Related Items
New Evidence of Racial and Ethnic Disparities Among Patients with Systemic Lupus Erythematosus
VBCR - October 2017, Vol 6, No 4 published on October 20, 2017 in Lupus
New Electronic Health Record Algorithms Accurately Identify Patients with Systemic Lupus Erythematosus
Alice Goodman
VBCR - June 2017, Vol 6, No 2 published on June 29, 2017 in Lupus
Patients with Systemic Lupus Erythematosus Should Be Monitored for Electrocardiogram Abnormalities
Alice Goodman
VBCR - April 2017, Vol 6, No 1 published on May 3, 2017 in Lupus
Addressing Health Issues in Women with Systemic Lupus Erythematosus and/or Antiphospholipid Syndrome
Sophie Granger
VBCR - April 2017, Vol 6, No 1 published on May 3, 2017 in Lupus
Mixed Cost Results with Repository Corticotropin Injection Therapy for Patients with SLE
Charles Bankhead
VBCR - August 2016, Vol 5, No 4 published on August 25, 2016 in Lupus
Cervical Neoplasia Screening Needed in Women with Systemic Lupus Erythematosus
Alice Goodman
VBCR - August 2016, Vol 5, No 4 published on August 25, 2016 in Lupus
Anifrolumab a Winner, So Far, for Severe Systemic Lupus Erythematosus
Alice Goodman
VBCR - August 2016, Vol 5, No 4 published on August 25, 2016 in Lupus
Age, Smoking History Are Risk Factors for Early Organ Damage in Patients with SLE
Phoebe Starr
VBCR - June 2016, Vol 5, No 3 published on July 7, 2016 in Lupus
5 Tips for Preventing Lupus Flares
VBCR - June 2016, Vol 5, No 3 published on July 7, 2016 in Lupus
Exercise, Psychotherapy Can Reduce Fatigue in Patients with Systemic Lupus Erythematosus
Alice Goodman
VBCR - February 2016, Vol 5, No 1 published on March 15, 2016 in Lupus
Last modified: May 21, 2015
  • Rheumatology Practice Management
  • Lynx CME
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology